Computational biology company Evogene Ltd. EVGN will release its financial results for the full year and fourth quarter of 2021 on March 10, 2022. On the day of the announcement, the company's management will host a conference call to discuss the results at 09:00 a.m. EST.
Evogene established three unique technological engines, MicroBoost AI, ChemPass AI and GeneRator AI. Each technological engine is focused on the discovery and development of products based on one of the following core components: microbes (Microboost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). The company uses its technological engines to develop products through subsidiaries and with strategic partners. Evogene's main subsidiaries utilize the technological engines to develop novel products as follows: human microbiome-based therapeutics by Biomica Ltd., medical cannabis by Canonic Ltd., ag-chemicals by AgPlenus and ag-biologicals by Lavie Bio Ltd.
Price Action
Evogene shares traded 1.63% higher at $1.25 per share at the time of writing Tuesday morning.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.